Crystal structures of cholesteryl ester transfer protein in complex with inhibitors.

The Journal of biological chemistry 20121026

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

Journal of lipid research 20120901

Rationale for cholesteryl ester transfer protein inhibition.

Current opinion in lipidology 20120801

HDL and CETP Inhibition: Will This DEFINE the Future?

Current treatment options in cardiovascular medicine 20120801

Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.

Journal of medicinal chemistry 20120712

Torcetrapib impairs endothelial function in hypertension.

European heart journal 20120701

De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?

European heart journal 20120701

Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.

European heart journal 20120701

An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.

Future cardiology 20120701

Evacetrapib.

Current cardiology reports 20120601

Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.

Journal of lipid research 20120601

Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.

Bioorganic & medicinal chemistry letters 20120601

Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.

Current clinical pharmacology 20120501

Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.

Bioorganic & medicinal chemistry letters 20120501

Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia.

Journal of cardiovascular pharmacology 20120401

Dalcetrapib--restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease.

Expert opinion on investigational drugs 20120401

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

European heart journal 20120401

Letter by McGuire and Aguilar regarding article, 'Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial'.

Circulation 20120306

Letter by Knop regarding article, 'Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial'.

Circulation 20120306

On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.

Drugs 20120305

Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.

Atherosclerosis 20120301

New horizons for cholesterol ester transfer protein inhibitors.

Current atherosclerosis reports 20120201

Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.

Current atherosclerosis reports 20120201

[HDL level or HDL function as the primary target in preventive cardiology].

Herz 20120201

Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease.

Experimental diabetes research 20120101

Anacetrapib, a cholesteryl ester transfer protein inhibitor.

Expert opinion on investigational drugs 20120101

Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.

PLoS computational biology 20120101

Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice.

PloS one 20120101

Translatability scoring in drug development: eight case studies.

Journal of translational medicine 20120101

Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.

PloS one 20120101

Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.

Nutrition & metabolism 20120101

Ethanolic Extract of Vitis thunbergii Exhibits Lipid Lowering Properties via Modulation of the AMPK-ACC Pathway in Hypercholesterolemic Rabbits.

Evidence-based complementary and alternative medicine : eCAM 20120101

Mixed dyslipidemias in primary care patients in France.

Vascular health and risk management 20120101

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

Vascular health and risk management 20120101

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

Core evidence 20120101

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.

Vascular health and risk management 20120101

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Drug design, development and therapy 20120101

Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach.

BMC systems biology 20120101

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.

Cardiovascular therapeutics 20111201

High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention.

Heart (British Cardiac Society) 20111201

CETP Inhibition: does the future look promising?

Current cardiology reports 20111201

Familial hypercholesterolemia: present and future management.

Current cardiology reports 20111201

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Journal of lipid research 20111201

Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.

Journal of lipid research 20111201

Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.

Atherosclerosis 20111201

Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

Trends in pharmacological sciences 20111201

CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.

Clinical and translational science 20111201

Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding.

PLoS computational biology 20111201

Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein.

Atherosclerosis 20111101

Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.

Expert opinion on investigational drugs 20111101

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

Lancet (London, England) 20111029

Anacetrapib: hope for CETP inhibitors?

Cardiovascular therapeutics 20111001

Cholesteryl-ester transfer protein enhances the ability of high-density lipoprotein to inhibit low-density lipoprotein oxidation.

IUBMB life 20110901

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints.

Heart (British Cardiac Society) 20110815

ILLUMINATE sheds more light.

Circulation 20110802

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Circulation 20110802

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Current opinion in lipidology 20110801

Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.

Current atherosclerosis reports 20110601

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

European heart journal 20110601

[Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope'].

Revista medica de Chile 20110601

The DEFINE study: a bright future for CETP inhibitors?

Expert opinion on investigational drugs 20110301

Learning lessons from Pfizer's $800 million failure.

Nature reviews. Drug discovery 20110301

A stronger role for science.

Nature reviews. Drug discovery 20110301

IVUS-based imaging modalities for tissue characterization: similarities and differences.

The international journal of cardiovascular imaging 20110201

Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond.

The international journal of cardiovascular imaging 20110201

Trial watch: hope renewed for strategy to raise HDL cholesterol.

Nature reviews. Drug discovery 20110101

Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.

The Annals of pharmacotherapy 20110101

Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.

Trials 20110101

Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.

Lipids in health and disease 20110101

Cardiovascular disease and dyslipidemia: beyond LDL.

Current pharmaceutical design 20110101

Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response.

Cholesterol 20110101

Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds.

Journal of cheminformatics 20110101

A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women.

Lipids in health and disease 20110101

Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

The open cardiovascular medicine journal 20110101

High-density lipoprotein proteome dynamics in human endotoxemia.

Proteome science 20110101

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Drug design, development and therapy 20110101

A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.

BMC systems biology 20110101

Where are we heading with noninvasive clinical vascular physiology? Why and how should we assess endothelial function?

Cardiology research and practice 20110101

Emerging therapeutic strategies to enhance HDL function.

Lipids in health and disease 20110101

New insights into the mechanism of low high-density lipoprotein cholesterol in obesity.

Lipids in health and disease 20110101

Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

Probucol alleviates atherosclerosis and improves high density lipoprotein function.

Lipids in health and disease 20110101

Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.

PloS one 20110101

Safety of anacetrapib in patients with or at high risk for coronary heart disease.

The New England journal of medicine 20101216

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.

Journal of lipid research 20101201

[HDL: the yin-yang of cardiovascular disease].

Arquivos brasileiros de endocrinologia e metabologia 20101201

Good news for 'good' cholesterol.

Nature 20101118

The relationship between cholesteryl ester transfer protein and cardiovascular risk.

Clinical chemistry 20101001

Cholesteryl ester transfer protein antagonism by drugs--a poor choice.

Clinical chemistry 20101001

Off-target effects of torcetrapib.

Nature reviews. Cardiology 20101001

Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Journal of lipid research 20100901

Cholesteryl ester transfer protein and its inhibition.

Cellular and molecular life sciences : CMLS 20100901

Aldosterone, hypertension and heart failure: insights from clinical trials.

Hypertension research : official journal of the Japanese Society of Hypertension 20100901

Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.

Annals of medicine 20100901

Raising high-density lipoprotein: for better or worse?

Heart (British Cardiac Society) 20100901

Drug off-target effects predicted using structural analysis in the context of a metabolic network model.

PLoS computational biology 20100901

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.

Journal of hypertension 20100801

Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?

Current hypertension reports 20100801

A comparison of the chronic effects of human pharmaceuticals on two cladocerans, Daphnia magna and Ceriodaphnia dubia.

Chemosphere 20100801

Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?

Journal of hypertension 20100801

High-density lipoprotein therapy: is there hope?

Current treatment options in cardiovascular medicine 20100801

Dissociating HDL cholesterol from cardiovascular risk.

Lancet (London, England) 20100731

Obstacles and options in the quest for drug candidates against vascular disease.

Thrombosis and haemostasis 20100701

Comparison of telemetry and high-definition oscillometry for blood pressure measurements in conscious dogs: effects of torcetrapib.

Journal of the American Association for Laboratory Animal Science : JAALAS 20100701

[High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].

MMW Fortschritte der Medizin 20100701

Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.

Journal of cardiovascular pharmacology and therapeutics 20100601

Dalcetrapib: a review of Phase II data.

Expert opinion on investigational drugs 20100601

Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension.

Mayo Clinic proceedings 20100601

Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?

Expert review of cardiovascular therapy 20100601

Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection.

Journal of lipid research 20100501

Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.

Journal of cardiovascular pharmacology 20100501

Cholesteryl ester transfer protein inhibition: a dysfunctional endothelium.

Journal of cardiovascular pharmacology 20100501

Therapy: raising HDL cholesterol levels: a flight of Icarus?

Nature reviews. Endocrinology 20100501

Novel tetrahydrochinoline derived CETP inhibitors.

Bioorganic & medicinal chemistry letters 20100301

Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?

Expert review of cardiovascular therapy 20100301

Aldosterone, sodium, and hypertension: lessons from torcetrapib?

Hypertension (Dallas, Tex. : 1979) 20100201

[HDL and CETP in atherogenesis].

Deutsche medizinische Wochenschrift (1946) 20100201

Functional assessment of HDL: Moving beyond static measures for risk assessment.

Cardiovascular drugs and therapy 20100201

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

European heart journal 20100201

Regulation of glucose control in people with type 2 diabetes: a review and consensus.

Korean diabetes journal 20100201

Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.

Circulation 20100105

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Diabetes care 20100101

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

European heart journal 20100101

Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.

Vascular health and risk management 20100101

Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability.

Lipids in health and disease 20100101

Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.

Lipids in health and disease 20100101

Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk.

Journal of clinical lipidology 20100101

Niacin or ezetimibe for patients with, or at risk of coronary heart disease.

Clinical Medicine Insights. Cardiology 20100101

Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.

Journal of clinical lipidology 20100101

Update on CETP inhibition.

Journal of clinical lipidology 20100101

Low high-density lipoprotein cholesterol: current status and future strategies for management.

Vascular health and risk management 20100101

Treatment of dyslipidemia in patients with type 2 diabetes.

Lipids in health and disease 20100101

High density lipoproteins-based therapies for cardiovascular disease.

Journal of cardiovascular disease research 20100101

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

Controversy on high density lipoprotein raising therapy.

Romanian journal of internal medicine = Revue roumaine de medecine interne 20100101

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.

Drug, healthcare and patient safety 20100101

The grand challenges in cardiovascular drug discovery and development.

Frontiers in pharmacology 20100101

Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs.

Journal of cardiovascular pharmacology 20091201

Aldosterone and cardiovascular risk.

Current hypertension reports 20091201

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.

British journal of pharmacology 20091201

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

The American journal of cardiology 20091116

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.

The American journal of cardiology 20091116

The effects of cholesterol ester transfer protein inhibition on cholesterol efflux.

The American journal of cardiology 20091116

Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Journal of lipid research 20091101

Triglycerides and HDL cholesterol: stars or second leads in diabetes?

Diabetes care 20091101

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

Expert opinion on therapeutic patents 20090901

Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.

Current opinion in investigational drugs (London, England : 2000) 20090901

A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.

Biochemical pharmacology 20090815

Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.

Journal of lipid research 20090701

The end of the road for CETP inhibitors after torcetrapib?

Current opinion in cardiology 20090701

Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.

American heart journal 20090701

Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.

Current cardiology reports 20090701

Safety and tolerability of dalcetrapib.

The American journal of cardiology 20090701

Reverse cholesterol transport in type 2 diabetes mellitus.

Diabetes, obesity & metabolism 20090601

Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.

Current opinion in lipidology 20090601

Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.

Journal of cardiovascular pharmacology 20090601

Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies.

Bioanalysis 20090601

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.

Endocrinology 20090501

The off-target effects of torcetrapib.

Endocrinology 20090501

Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.

PLoS computational biology 20090501

Chiral Brønsted acid-catalyzed enantioselective three-component Povarov reaction.

Journal of the American Chemical Society 20090408

The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis.

Journal of lipid research 20090401

Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.

Journal of medicinal chemistry 20090326

['The lower LDL cholesterol levels, the better' still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].

Lakartidningen 20090301

Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.

Arteriosclerosis, thrombosis, and vascular biology 20090201

The hypertension peril: lessons from CETP inhibitors.

Current hypertension reports 20090201

New thinking in the development of novel derivatization reagents for liquid chromatography-mass spectrometric detection.

Biomedical chromatography : BMC 20090101

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.

Thrombosis research 20090101

High-density lipoprotein: why all the fuss?

Annals of clinical biochemistry 20090101

High-density lipoprotein/apolipoprotein A-I infusion therapy.

Current atherosclerosis reports 20090101

A review of trials evaluating nonstatin lipid-lowering therapies.

Current atherosclerosis reports 20090101

Is high HDL cholesterol always good?

Annals of medicine 20090101

Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries.

BMC genomics 20090101

[Laboratory assessment of HDL heterogeneity and function].

Annales de biologie clinique 20090101

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.

BMJ (Clinical research ed.) 20090101

High-density lipoprotein cholesterol: current perspective for clinicians.

Angiology 20090101

Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome.

Cerebrovascular diseases (Basel, Switzerland) 20090101

The independent relationship between triglycerides and coronary heart disease.

Vascular health and risk management 20090101

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.

Vascular health and risk management 20090101

Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor.

European journal of drug metabolism and pharmacokinetics 20090101

LDL-Cholesterol is the King.

Angiology 20090101

The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms.

The open cardiovascular medicine journal 20090101

Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy.

Lipids in health and disease 20090101

Regulation of bile acid and cholesterol metabolism by PPARs.

PPAR research 20090101

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.

International journal of biological sciences 20090101

Predicting drug side-effects by chemical systems biology.

Genome biology 20090101

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.

Vascular health and risk management 20090101

Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.

Current medicinal chemistry 20090101

An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI.

International journal of biological sciences 20090101

Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis.

BMC medical genetics 20090101

Complex disease genetics: present and future translational applications.

Genome medicine 20090101

Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Lipids in health and disease 20090101

Raising HDL cholesterol in women.

International journal of women's health 20090101

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).

Circulation 20081209

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Circulation 20081209

Leapfrogging data: no shortcuts for safety or efficacy information.

Circulation 20081209

Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes.

Pharmacogenetics and genomics 20081201

Current and emerging paradigms in the therapeutic management of atherosclerosis.

Expert opinion on therapeutic targets 20081201

Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans.

Drug metabolism and disposition: the biological fate of chemicals 20081101

Renin-angiotensin-aldosterone responsiveness to low sodium and blood pressure reactivity to angiotensin-II are unrelated to cholesteryl ester transfer protein mass in healthy subjects.

Expert opinion on therapeutic targets 20081101

Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?

Cardiology clinics 20081101

HDL-cholesterol levels and cardiovascular risk: acCETPing the context.

European heart journal 20081101

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.

European heart journal 20081101

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Postgraduate medical journal 20081101

Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.

Drug metabolism and disposition: the biological fate of chemicals 20081001

The failure of torcetrapib: is there a case for independent preclinical and clinical testing?--correspondence.

Expert opinion on pharmacotherapy 20081001

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Expert opinion on investigational drugs 20081001

HDL: still a target for new therapies?

Current opinion in investigational drugs (London, England : 2000) 20080901

HDL-cholesterol: is it really good? Differences between apoA-I and HDL.

Biochemical pharmacology 20080815

The failure of torcetrapib: what have we learned?

British journal of pharmacology 20080801

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

British journal of pharmacology 20080801

Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

Cardiovascular drugs and therapy 20080801

Effect of torcetrapib in patients at high risk for coronary events.

Current atherosclerosis reports 20080801

HDL metabolism in context: looking on the bright side.

Current opinion in lipidology 20080801

Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein.

Bioconjugate chemistry 20080801

Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?

Diabetes technology & therapeutics 20080801

[Can cardiovascular events be prevented by raising HDL cholesterol?].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080626

Redefining quality--implications of recent clinical trials.

The New England journal of medicine 20080612

Spotlight on HDL-raising therapies: insights from the torcetrapib trials.

Nature clinical practice. Cardiovascular medicine 20080601

Time to rethink high-density lipoprotein?

Heart (British Cardiac Society) 20080601

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Heart (British Cardiac Society) 20080601

Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?

Current atherosclerosis reports 20080601

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.

Circulation 20080513

[Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].

Nederlands tijdschrift voor geneeskunde 20080510

Laboratory assessment of HDL heterogeneity and function.

Clinical chemistry 20080501

Synthetic HDL as a new treatment for atherosclerosis regression: has the time come?

Nutrition, metabolism, and cardiovascular diseases : NMCD 20080501

The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.

Expert opinion on pharmacotherapy 20080501

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

Cell metabolism 20080501

Torcetrapib and coronary events.

The New England journal of medicine 20080424

Torcetrapib and coronary events.

The New England journal of medicine 20080424

Torcetrapib and coronary events.

The New England journal of medicine 20080424

Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging.

Atherosclerosis 20080401

Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.

Current opinion in endocrinology, diabetes, and obesity 20080401

Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment.

Current opinion in endocrinology, diabetes, and obesity 20080401

Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?

Expert opinion on investigational drugs 20080401

The failure of torcetrapib: is there a case for independent preclinical and clinical testing?

Expert opinion on pharmacotherapy 20080401

Will CETP inhibition survive the demise of torcetrapib?

Current atherosclerosis reports 20080401

Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.

JAMA 20080326

Development of a self-emulsifying formulation that reduces the food effect for torcetrapib.

International journal of pharmaceutics 20080303

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.

Journal of lipid research 20080301

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

Cardiovascular research 20080301

Development and validation of a sensitive LC-MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma.

Biomedical chromatography : BMC 20080301

High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.

Cardiovascular research 20080301

Lessons from torcetrapib: putting patient-oriented evidence first.

American family physician 20080301

Torcetrapib: when global risk reduction goes 'off target'.

International journal of clinical practice 20080201

Is raising HDL a futile strategy for atheroprotection?

Nature reviews. Drug discovery 20080201

Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone.

Journal of clinical hypertension (Greenwich, Conn.) 20080201

Torcetrapib and the progression of coronary atherosclerosis.

Current atherosclerosis reports 20080201

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.

Vascular health and risk management 20080201

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.

Arteriosclerosis, thrombosis, and vascular biology 20080101

The conscientious judgement of a DSMB--statistical stopping rules re-examined.

European journal of clinical pharmacology 20080101

Three drug indications for patients with peripheral arterial disease bite the dust: report from the American Heart Association meeting 2007 in Orlando.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20080101

Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.

Journal of the American College of Cardiology 20080101

HDL metabolism and CETP inhibition.

Cardiology in review 20080101

High-density lipoprotein: a fall from grace?

Annals of medicine 20080101

Pharmacologic management of isolated low high-density lipoprotein syndrome.

American journal of therapeutics 20080101

Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Arthritis research & therapy 20080101

Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.

Lipids in health and disease 20080101

Fused-core particles: a practical alternative to sub-2 micron particles.

Journal of chromatographic science 20080101

Chiral bioanalysis of torcetrapib enantiomers in hamster plasma by normal-phase liquid chromatography and detection by atmospheric pressure chemical ionization tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071215

CETP inhibition.

Lancet (London, England) 20071208

Regulatory considerations in the development of high-density lipoprotein therapies.

The American journal of cardiology 20071203

Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.

The American journal of cardiology 20071203

Refocusing on use of cholesteryl ester transfer protein inhibitors.

The American journal of cardiology 20071203

When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.

Current atherosclerosis reports 20071201

[Reading medical articles--what pitfalls to avoid].

Revue medicale suisse 20071128

Effects of torcetrapib in patients at high risk for coronary events.

The New England journal of medicine 20071122

Illuminating HDL--is it still a viable therapeutic target?

The New England journal of medicine 20071122

HDL elevation and lipid lowering therapy: current scenario and future perspectives.

Recent patents on cardiovascular drug discovery 20071101

Development and validation of an enantioselective HPLC-UV method using Chiralpak AD-H to quantify (+)- and (-)-torcetrapib enantiomers in hamster plasma--application to a pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071001

The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism.

Expert opinion on investigational drugs 20071001

Does torcetrapib reduce the progression of atherosclerotic disease?

Nature clinical practice. Cardiovascular medicine 20070901

The continuing complexities of high-density lipoprotein metabolism in drug discovery and development.

Expert opinion on therapeutic targets 20070901

A concise asymmetric synthesis of torcetrapib.

The Journal of organic chemistry 20070803

The role of CETP inhibition in dyslipidemia.

Current atherosclerosis reports 20070801

HDL cholesterol and atherosclerosis.

Lancet (London, England) 20070714

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Lancet (London, England) 20070714

Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?

Current opinion in cardiology 20070701

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.

Journal of lipid research 20070601

Development of torcetrapib, a lipid-lowering drug, abandoned.

Prescrire international 20070601

Man on a mission.

Nature 20070531

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Arteriosclerosis, thrombosis, and vascular biology 20070501

World Hypertension Day 2007.

Hypertension (Dallas, Tex. : 1979) 20070501

Where now for new drugs for atherosclerosis?

Nature reviews. Drug discovery 20070501

HDL: back to the drawing board.

The Johns Hopkins medical letter health after 50 20070501

Peptide Mimetics of Apolipoproteins Improve HDL Function.

Journal of clinical lipidology 20070501

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

The New England journal of medicine 20070419

New clues to HDL's benefits revealed.

JAMA 20070411

Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development.

Journal of thrombosis and thrombolysis 20070401

Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.

Harvard health letter 20070401

Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.

Current medical research and opinion 20070401

Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib.

Urologic nursing 20070401

Effect of torcetrapib on the progression of coronary atherosclerosis.

The New England journal of medicine 20070329

CETP inhibitors to increase HDL cholesterol levels.

The New England journal of medicine 20070329

Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.

Current drug targets 20070301

New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.

Harvard heart letter : from Harvard Medical School 20070301

[Advances in the study of anti-atherosclerosis drugs].

Yao xue xue bao = Acta pharmaceutica Sinica 20070301

Early termination of drug trials.

BMJ (Clinical research ed.) 20070217

CETP inhibition in cardiovascular risk management: a critical appraisal.

European journal of clinical investigation 20070201

The failure of torcetrapib: was it the molecule or the mechanism?

Arteriosclerosis, thrombosis, and vascular biology 20070201

Drug designed to raise HDL levels falls down.

The Journal of clinical investigation 20070201

When the party's over.

Nature 20070104

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.

European heart journal 20070101

Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Current atherosclerosis reports 20070101

Intensive statin treatment or combination therapy in high-risk patients.

Preventive cardiology 20070101

The hypertension peril and drug development.

American journal of therapeutics 20070101

The strange case of Dr HDL and Mr HDL: does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP?

Medical hypotheses 20070101

'Linkage' pharmaceutical evergreening in Canada and Australia.

Australia and New Zealand health policy 20070101

Analysis of arterial intimal hyperplasia: review and hypothesis.

Theoretical biology & medical modelling 20070101

Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients - the Hong Kong diabetes registry.

Cardiovascular diabetology 20070101

The 'forgotten' bile acid sequestrants: is now a good time to remember?

American journal of therapeutics 20070101

Increasing HDL: the torcetrapib story.

Cardiology journal 20070101

Solving the HDL mystery.

U.S. news & world report 20061218

Pfizer stops clinical trials of heart drug.

BMJ (Clinical research ed.) 20061216

Cholesterol: the good, the bad, and the stopped trials.

Lancet (London, England) 20061209

The potential for CETP inhibition to reduce cardiovascular disease risk.

Current medical research and opinion 20061201

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.

Journal of the American College of Cardiology 20061107

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.

Journal of the American College of Cardiology 20061107

Cholesteryl ester transfer protein inhibition: the next frontier in combating coronary artery disease?

Journal of the American College of Cardiology 20061107

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.

Pharmacology & therapeutics 20060901

Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.

Current opinion in lipidology 20060801

Prevention challenges: the era of atherosclerosis regression.

The Canadian journal of cardiology 20060801

[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].

MMW Fortschritte der Medizin 20060615

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.

Arteriosclerosis, thrombosis, and vascular biology 20060601

Lipid-lowering drugs.

Cellular and molecular life sciences : CMLS 20060501

The in vitro plasma distribution of a novel cholesteryl ester transfer protein inhibitor, torcetrapib, is influenced by differences in plasma lipid concentrations.

Pharmaceutical research 20060501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060501

Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.

Current opinion in pharmacology 20060401

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action.

Journal of lipid research 20060301

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.

Journal of the American College of Cardiology 20060207

Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease.

Expert opinion on investigational drugs 20060201

Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.

Drugs of today (Barcelona, Spain : 1998) 20060201

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

Cardiovascular diabetology 20060101

New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib.

Recent patents on cardiovascular drug discovery 20060101

K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.

Core evidence 20060101

Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?

Current drug targets. Cardiovascular & haematological disorders 20051201

2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.

Diabetes care 20051101

Novel variants in human and monkey CETP.

Biochimica et biophysica acta 20051015

Torcetrapib and atorvastatin.

The New England journal of medicine 20051006

Torcetrapib and atorvastatin.

The New England journal of medicine 20051006

Torcetrapib and atorvastatin.

The New England journal of medicine 20051006

Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.

Arteriosclerosis, thrombosis, and vascular biology 20051001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051001

Torcetrapib/atorvastatin combination therapy.

Expert review of cardiovascular therapy 20050901

Torcetrapib + atorvastatin (Pfizer).

Current opinion in investigational drugs (London, England : 2000) 20050901

Torcetrapib and atorvastatin--should marketing drive the research agenda?

The New England journal of medicine 20050623

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050601

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

Arteriosclerosis, thrombosis, and vascular biology 20050501

Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib.

The Journal of biological chemistry 20050415

Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.

Current atherosclerosis reports 20050201

Lipid transfer proteins (LTP) and atherosclerosis.

Atherosclerosis 20050201

Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review.

Cardiovascular diabetology 20050101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050101

Role of CETP inhibitors in the treatment of dyslipidemia.

Current opinion in lipidology 20041201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20041201

Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease.

Expert opinion on investigational drugs 20041001

Experimental drug can double levels of 'good' cholesterol. But does torcetrapib cut the risk of heart disease?

Health news (Waltham, Mass.) 20040601

Molecule of the month. Torcetrapib.

Drug news & perspectives 20040601

S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.

Bioorganic & medicinal chemistry letters 20040517

Procalcitonin and infective endocarditis.

Circulation 20040413

Increasing HDL Cholesterol Levels.

The New England journal of medicine 20040408

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

The New England journal of medicine 20040408

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.

Arteriosclerosis, thrombosis, and vascular biology 20040301

High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease.

Arteriosclerosis, thrombosis, and vascular biology 20040301

Pharmacotherapy for dyslipidaemia--current therapies and future agents.

Expert opinion on pharmacotherapy 20031101